Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Mutant Huntingtin and Neurofilament Light Valid Biomarkers in Huntington’s Disease

Key clinical point: Mutant huntingtin and plasma and cerebrospinal fluid levels of neurofilament light are useful biomarkers in Huntington’s disease.

Major finding: Levels of neurofilament light in plasma are correlated with those in cerebrospinal fluid.

Study details: A prospective, observational cohort study including 80 participants with and without Huntington’s disease.

Disclosures: No funding for this study was reported.


Rodrigues FB et al. AAN 2019, Abstract S16.003.